ProCE Banner Activity

Larotrectinib in Patients With TRK Fusion–Positive Lung Cancer

Slideset Download
Conference Coverage
Expanded analysis of cohort of patients with TRK fusion–positive lung cancer who received larotrectinib in a phase I or II basket trial suggests rapid, durable activity with larotrectinib, including in patients with CNS disease.

Released: September 15, 2021

Expiration: September 14, 2022

No longer available for credit.

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AstraZeneca

Bayer Healthcare Pharma

Daiichi Sankyo, Inc.

Janssen administered by Scientific Affairs

Janssen Pharmaceutica NV

Millennium Pharmaceuticals Inc Subsidary of Takeda

Regeneron Pharmaceuticals, Inc. and Sanofi Genzyme